Lurbinectedin improves macular edema in a case of central retinal vein occlusion

鲁比奈德定可改善中心性视网膜静脉阻塞引起的黄斑水肿

阅读:1

Abstract

PURPOSE: To evaluate the response to lurbinectedin in a case of macular edema, secondary to central retinal vein occlusion (CRVO). Serial spectral domain optical coherence tomography (SD-OCT) scans were taken in a 70-year-old man with a 24-month history of macular edema secondary to CRVO in the right eye. The patient underwent 5 cycles of chemotherapy with lurbinectedin between October 2018 and May 2019. Central macular thickness (CMT) before and after each chemotherapy cycle was measured together with progression analysis using the CIRRUS Zeiss software. OBSERVATIONS: SD-OCT showed alternating recurrence and resolution of macular edema closely related to the chemotherapy administrations. CMT oscillated between 496 and 284 μm during the follow-up. The macular edema was showed to decrease as soon as 4 days following chemotherapy. CONCLUSIONS AND IMPORTANCE: Resolution of macular edema associated with CRVO was seen in our patient whilst undergoing chemotherapy with lurbinectedin. Lurbinectedin may play a role in the treatment of macular edema secondary to CRVO and may open new therapeutic indication for this natural marine molecule.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。